New Jersey-based Catalent Inc. (NYSE: CTLT) is announcing a major expansion of its biologics manufacturing operations in Bloomington and plans to create up to 200 jobs by the end of 2024.
The drug development, delivery and supply company will expand its substance manufacturing capacity and product fill/finish capacity to keep up with projected growth among existing and future customers. Catalent plans to invest over $100 million in its Bloomington operations, growing the site’s packaging capabilities and manufacturing capacity to support customer demands. Construction is expected to conclude in April 2019.
“Indiana is the second largest exporter of life sciences products in the U.S. and is recognized as a world leader in the industry because of companies like Catalent,” Governor Eric J. Holcomb said in a news release. “This expansion is yet another example of how Indiana’s pro-business environment and skilled workforce deliver the resources that life science companies need to compete in the global marketplace. With the expansion of Catalent’s packaging and manufacturing capabilities, the company will increase its operations while creating high-tech careers for Hoosiers.”
Catalent is eligible to receive up to $2.4 million in conditional tax credits based on the company’s job creation plans. The Indiana Economic Development Corporation will award these tax credits on a performance-based basis, and Catalent will not receive them until Hoosiers are hired.
The company currently employs 900 people at the Bloomington and is currently taking applications. Interested applicants can learn more and apply online by clicking here.